All ALK inhibitors were solely been indicated for patients with ALK-positive tumours (defined by a validated method), whereas EGFR inhibitors (specifically erlotinib) were also used to some extent outside of EGFR-positive patients [26]. The gene discussed is EGFR; the disease is neoplasm.